Drug Profile
Research programme: cancer therapeutics - Massachusetts General Hospital/Sanofi
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Massachusetts General Hospital; Sanofi
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Haematological-malignancies in France
- 16 Jul 2016 No recent reports of development identified for research development in Haematological-malignancies in USA
- 16 Jul 2016 No recent reports of development identified for research development in Solid-tumours in France